Based on our findings, we propose the following recommendations for clinicians when considering UBA: First, UBA is indicated in cases of demonstrable SUI. Intrinsic sphincter deficiency is not predictive of patient outcomes. Second, patients should be counseled on the risks, lack of long-term efficacy data, potential need for repeat injections, possible need for surgery for recurrent SUI, implications for future procedures, and pelvic imaging findings that may be observed after UBA. Third, UBA may be considered for initial management of SUI. Fourth, UBA is an option for patients with persistent or recurrent SUI after a sling procedure. Fifth, clinicians may prioritize UBA over surgery in specific patient populations. Sixth, polyacrylamide hydrogel demonstrates marginally improved safety and durability data over other available agents.
Keyphrases
- minimally invasive
- coronary artery bypass
- end stage renal disease
- urinary incontinence
- electronic health record
- chronic kidney disease
- newly diagnosed
- ejection fraction
- high resolution
- drug delivery
- human health
- climate change
- clinical practice
- deep learning
- acute coronary syndrome
- artificial intelligence
- current status
- hyaluronic acid
- wound healing